The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
“It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market ...
Months after Massachusetts voters rejected a ballot question that would permit adults to use and grow certain psychedelic drugs, some state lawmakers have begun proposing bills to legalize psilocybin.
Research also suggests that esketamine nasal spray doesn’t affect thinking skills the way high doses of ketamine do. What’s Next Along with treatment-resistant depression, Spravato is approved ...
Pay-Per-Click (PPC) Management: Targeted PPC campaigns across platforms like Google and social media, focusing on treatments such as ketamine infusion, Spravato (Esketamine), TMS therapy ...
The US FDA has approved the first of its kind ketamine-based nasal spray which ... the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...
According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ... behind them that the treatments work,” Merrill said. “Ketamine is a safe medication when used under appropriate professional ...
If esketamine seems familiar, that’s probably because it’s a component of ketamine. It was once popular as a party drug called Special K. Fortunately, Spravato underwent 31 clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results